Company intelligence / Profile preview
Mendus
Stockholm, Swedenmendus.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Mendus has demonstrated promising Phase II clinical data with its lead asset vididencel, particularly showing potential to reduce tumor recurrence and improve long-term survival in cancer patients. The company received positive feedback from both the FDA and EMA regarding registration trial preparations for vididencel in AML. Preparations are underway for pivotal-stage studies.
- Therapeutic areas
- Oncology
- Modalities
- Dendritic cell-based immunotherapies
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Beyond the preview
Go deeper on Mendus.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Mendus.